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the CFSE assay. The critical advantage of the CFSE assay
over the 3H-thymidine assay is its substantially higher sig-
nal to noise-ratio [3–6]. For the full argument on why the
CFSE assay is much more meaningful than the 3H-thymi-
dine assay, we refer to Sakaguchi et al. [3] who summarise
‘‘that thymidine uptake by cultured Treg and effector cells is
not appropriate to assess suppressive activity of human Treg
cells’’, and instead ‘‘propose that it is more accurate to assess
dilution of CFSE in effector T cells to determine the percentage
and number of proliferating cells’’.
(3) We read with great surprise the remark by Ferri et al. that,
for performing the CFSE assay, we did not provide data ‘‘to
assess the efﬁciency of the puriﬁcation’’ or whether the ‘‘puri-
ﬁed cells are CD127low’’. In contrast to Ferri et al., who did
not analyse the CD127 status of the puriﬁed cells, we did
characterise both the puriﬁed Treg cells and the puriﬁed
non-Treg cells for expression of CD127. This was clearly
stated in our paper and a representative analysis of FOXP3
and CD127 status of the puriﬁed cells is shown in Fig. 2A of
our paper.
(4) Ferri et al. criticise the fact that we used a Treg/T
effector ratio of 1:1 in our suppressor assay, which is not
supposed to reﬂect the Treg frequency in peripheral blood.
However, the Treg frequency in blood is irrelevant for
their suppressor function. Treg cells do not suppress on
the ﬂy while ﬂowing with the blood stream; they suppress
mainly through cell contact between one cell and another
within (lymphoid) tissues. Consequently, as others have
shown [4–6], the suppressive potential of Treg cells can
be reasonably assessed with the CFSE assay at a ratio of
1:1.
(5) Ferri et al. reported the presence of FOXP3+ cells in the liv-
ers of 5/7 AIH patients, but did not make a comparison
with other inﬂammatory liver diseases. We ﬁnd that the
numbers of FOXP3+ cells were signiﬁcantly higher in AIH
livers than in NASH livers, and that the number of FOXP3+
cells in the liver correlated with histological disease
activity.
In summary, we have reasons to believe that the methodology
used by us was appropriate and that the conclusions drawn from
these experiments are valid.
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Mid-regional pro-adrenomedullin (MR-proADM): An even
better prognostic biomarker than C-reactive protein to predict
short-term survival in patients with decompensated
cirrhosis at risk of infection?
Letters to the EditorTo the Editor:
We read with great interest the study by Cervoni et al. [1]
investigating C-reactive protein (CRP) as a prognostic marker of
short-term mortality in patients with advanced cirrhosis.
Although persistently elevated CRP levels discriminated patients
with poor prognosis due to presumably ongoing systemic inﬂam-
mation, in their study, baseline CRP was less accurate discrimi-
nating bacterial infection and its hemodynamic and renal
complications, which substantially contribute to the increased
mortality in patients with cirrhosis and might be discriminated
using novel biomarkers. A candidate biomarker is the mid-regio-1156 Journal of Hepatology 20nal fragment of pro-adrenomedullin (MR-proADM), which has
been demonstrated to be an excellent predictor of short-term
mortality in patients with sepsis [2], lower respiratory tract infec-
tions [3] and critically ill patients with new-onset fever [4].
MR-proADM is the non-functional, more stable precursor pep-
tide of adrenomedullin, a vasoactive calcitonin peptide family
member that is rapidly cleared from circulation [5]. Circulating
adrenomedullin mainly originates from endothelial cells and
vascular smooth muscle cells and is upregulated under inﬂam-
matory stimuli mediated by pro-inﬂammatory cytokines or bac-
terial endotoxin, under hypervolemia and during tissue hypoxia12 vol. 57 j 1152–1159
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[6]. It exerts its vasoactive functions via dilatation of resistance
and capacitance vessels including mesentery vessels, stimulation
of NO synthesis, and increase of cardiac output [6]. Studies sug-
gest that adrenomedullin may also have direct antibacterial prop-
erties on mucosal surfaces [7]. Although adrenomedullin plasma
concentrations are increased in end-stage liver disease and corre-
late with hemodynamic, renal, and neurohumoral impairment in
patients with cirrhosis and ascites [8–10], the prognostic rele-
vance of MR-proADM in patients with advanced cirrhosis and
its correlation with bacterial infections and circulating CRP levels
have not been evaluated yet.
We, therefore, determined MR-proADM and CRP concentra-
tions in serum samples from 213 consecutive hospitalized
patients with cirrhosis and ascites that underwent diagnostic
paracentesis for suspected bacterial infection using an automated
immunoﬂuorescent assay (BRAHMS, Henningsdorf, Germany).
Patients (median age 59 years; range: 24–90) were predomi-
nantly male (73%) with alcoholic cirrhosis (77%) and had a med-
ian MELD score of 17 (range: 6–40) and a median Child–Pugh
score of 10 points (range: 7–15). 34 (16%) patients presented
with spontaneous bacterial peritonitis (SBP), 76 (36%) with other
bacterial infections including pneumonia, bacteremia, cholangi-
tis, urinary tract, and skin infections and 103 (48%) patients had
no detectable infectious focus. Systemic inﬂammatory response
syndrome (SIRS) was diagnosed in a total of 96 (45%) patients.
MR-proADM positively correlated with CRP (rs = 0.332;
p <0.001), interleukin-6 (rs = 0.256; p = 0.010), and white blood
cell count (rs = 0.181; p = 0.008) but also with impaired renal
(serum creatinine: rs = 0.507; p <0.001) and liver function (INR:
rs = 0.156; p = 0.023) in non-parametric correlation. MR-proADM
concentrations were higher in patients with SBP irrespective of
the presence of SIRS (Fig. 1A), whereas higher CRP levels were
found in patients with SBP as well as with other bacterial infec-
tions or SIRS (Fig. 1B). While CRP was a good predictor of overt
bacterial infection (area under the ROC curve [AUROC] 0.772;
95% CI: 0.711–0.834), MR-proADM was a poor predictor of bacte-
rial infection in general (AUROC 0.579; 95% CI: 0.503–0.656), but
an acceptable predictor of SBP in particular (0.719; 95% CI:
0.622–0.816).
Within 30 days after paracentesis, 46 (22%) patients died,
seven underwent liver transplantation and one was lost to fol-
low-up. MR-proADM concentrations were higher in non-survi-
vors than in survivors independently of the occurrence of SBP
at baseline (Fig. 1C), while CRP levels were only higher in patients
with SBP-related death but did not statistically signiﬁcant differ
between survivors and non-survivors without SBP at baseline
(Fig. 1D). Median MR-proADM levels were identical in the 33
patients with hepatocellular carcinoma (1.7 nmol/L) compared
to patients without hepatocellular carcinoma (1.8 nmol/L;
p = 0.715). The area under the ROC curve for MR-proADM to pre-
dict 30-day mortality was higher (0.757; 95% CI: 0.675–0.838)
than for CRP (0.712; 95% CI: 0.626–0.797) and for the MELD score
(0.703; 95% CI: 0.612–0.795). In multivariate logistic regression,
MR-proADM predicted 30-day mortality (OR 1.196 per 1 nmol/L
increase; 95% CI: 1.028–1.392; p = 0.020) independently of the
MELD score (OR 1.071 per 1-point increase; 95% CI: 1.019–
1.127; p = 0.007), presence of SIRS (OR 2.313; 95% CI: 1.075–
4.978; p = 0.032) and ongoing bacterial infection (OR 3.190; 95%
CI: 1.407–7.234; p = 0.005).
Our data indicate that, in contrast to CRP, which is frequently
elevated in advanced cirrhosis due to ongoing systemic inﬂam-
Journal of Hepatology 20mation or bacterial infection, MR-proADM is a promising surro-
gate marker to identify patients with complicated bacterial
infections as well as patients at risk of short-term mortality
independently of bacterial infections and SIRS occurrence. The
combined interpretation of CRP and MR-proADM may help dis-
criminate patients with persistent sterile systemic inﬂammation
from those with complicated bacterial infections in clinical
practice.
Fig. 1. MR-ProADM and CRP in patients with decompensated cirrhosis and
prediction of bacterial infections and 30-day mortality. Serum concentrations
of mid-regional pro-adrenomedullin (MR-proADM) and C-reactive protein (CRP)
in 213 patients with cirrhosis and ascites at the time of diagnostic paracentesis
are indicated and were stratiﬁed for (A and B) the type of bacterial infection and
the occurrence of systemic inﬂammatory response syndrome (SIRS) and (C and D)
for mortality within 30 days after measurement. Tukey boxplots or distribution
and median are shown. Horizontal dashed lines represent median MR-proADM
serum concentrations in non-infected patients (1.6 nmol/L) and the proposed CRP
concentration cut-off (29 mg/L) by Cervoni et al. [1], respectively. p values
represent results of Kruskal–Wallis test; pair-wise signiﬁcance levels of Dunns
post-hoc test are indicated (⁄⁄⁄p <0.001; ⁄p <0.05; n.s.: not signiﬁcant). SBP,
spontaneous bacterial peritonitis; LTX, liver transplantation.observational study. Crit Care 2005;9:R816–824.
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Reply to: ‘‘Mid-regional pro-adrenomedullin (MR-proADM): An
even better prognostic biomarker than C reactive protein to
predict short-term survival in patients with decompensated
cirrhosis at risk of infection?’’
To the Editor:
We thank Reuken et al. for their interest in our study. The prognos-
tic evaluation of cirrhotic patients has improved in the last decade
or so, with the consideration of extrahepatic complications com-
mon in cirrhosis, and with the dynamic assessment of prognostic
scores. The ﬁrst extrahepatic complication taken into account was
hepatorenal syndrome, justifying the incorporation of serum cre-
atinine in theMELD score. More recently, Arvaniti et al. proposed a
prognostic classiﬁcation in which bacterial infection deﬁned the
more severe stage of cirrhosis [1]. However, bacteriological tests
that are mandatory for the diagnosis of infection may lack sensi-
tivity in cirrhosis. Moreover, systemic inﬂammation associated
with bacterial infectionmay persist, even after appropriate antibi-
otic treatment, thus having an impact on prognosis. Recently, the
analysis of a large European cohort has conﬁrmed that the occur-
rence of an acute-on-chronic liver failure is associated with sys-
temic inﬂammation even in non-infected patients [2]. This is
why our study (1) focused on a marker of systemic inﬂammation
(rather than a marker of infection) and (2) considered as relevant
only the case of persistent elevation of CRP for 15 days [3].
New prognostic markers are currently under evaluation in cir-
rhosis. Most of them are inﬂuenced by systemic inﬂammation. For
example, our groupdemonstrated that elevated serumfree cortisol
is associatedwithhighCRP levels and increasedmortality inhemo-
dynamically stable cirrhotic patients [4]. Copeptin, a surrogate of
AVP secretion, also increases in the event of systemic inﬂammation
[5] and recently appeared as a promising prognostic marker in cir-
rhotic patients [6]. For all these new markers, it seems important
todeterminetheircorrelationwithCRP levels. Inaddition,essential
information for the clinician is their speciﬁc weight for prognosis,
independentofMELDandCRP. Indeed,althoughthesenewmarkers
appear attractive through their pathophysiological background,
they are not routinely available, conversely to CRP.
The results presented by Reuken et al. are very interesting but
deserve some comments. In their population including a majority
of infected patients (52%), the mid regional fragment of pro-adre-
nomedullin (MR-proADM) appeared to be a reliable marker of
spontaneous bacterial peritonitis (SBP). The authors emphasize
the relationship between MR-proADM and SBP rather than sys-
temic inﬂammation. We acknowledge that MR-proADM was a
better diagnostic marker of SBP than CRP. However, given the high
prevalence of infected patients and the more marked increase of
MR-proADM in the event of bacterial infection in the study of
Reuken et al. the prognostic value of MR-proADM remains to be
demonstrated in non-infected cirrhotic patients. The authors
should have provided speciﬁc data on this subgroup of patients.
Another comment concerns the statistical method used by the
authors. Their multivariate model seems questionable since
MR-proADM, bacterial infection, SIRS, and MELD were imple-
mented as independent variables, whereas univariate analyses
showed that MR-proADM was signiﬁcantly correlated with INR
and creatinine, and was a ‘‘poor’’ but signiﬁcant predictor of bac-
terial infection. Hence, the question of the true independent prog-
nostic value of MR-proADM remains unresolved. In our study, CRP
andMELDwere not collinear, thus allowing us to state that persis-
tently high CRP levels provided greater accuracy than the simple
measurement of MELD for evaluating prognosis in cirrhotic
patients.
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